We have been selected for the “Research and Development Program for Innovative Biologics” in 2024. 2024/09/12 Notice Read
Notice of a collaboration agreement with Renascience, Inc. to develop antisense oligonucleotides for treating hereditary neurological intractable diseases 2024/06/24 Notice Read
Notice：Luxna Biotech and Head Office for Open Innovation Business Development Strategy, Tohoku University Announce the Initiation of the Collaborative Research for Creation of Antisense Oligonucleotide for the Treatment of Hearing Loss 2023/12/22 Notice Read
We are selected as finalists for “Citeline Pharma Intelligence Awards Japan 2023”. 2023/09/26 Notice Read
